Advanced Therapy Medicinal Products (ATMPs) are reshaping modern healthcare, offering transformative treatments for cancers, genetic disorders, and previously untreatable conditions. However, from a quality oversight and GMP perspective, ATMPs operate under fundamentally different rules compared to traditional pharmaceuticals. Their biological complexity, patient-specific manufacturing models, and time-critical supply chains demand a more scientific, risk-based, and integrated approach to quality management. 

Quality Oversight for ATMPs – A Different Regulatory and Quality Paradigm

Advanced Therapy Medicinal Products (ATMPs), governed in the EU by Regulation (EC) No 1394/2007, include gene therapies, somatic cell therapies, and tissue-engineered products. These therapies challenge traditional pharmaceutical quality models by introducing high biological variability, complex manufacturing processes, and personalised treatment pathways. 

Unlike conventional pharmaceuticals, where quality oversight focuses on reproducibility and batch consistency, ATMP quality systems must manage variability, uncertainty, and rapid innovation while maintaining patient safety and regulatory compliance. 

ATMPs vs. Traditional Pharmaceuticals: Key Quality Differences 

ATMPs represent a rapidly expanding class of medicinal products designed to address complex and unmet medical needs. While their clinical potential is significant, their quality oversight requirements differ markedly from those applied to small-molecule or standard biologic products. 

Traditional pharmaceuticals are typically manufactured using well-defined, reproducible chemical processes that yield stable products with long shelf lives. In contrast, ATMPs are often derived from living cells or genetically modified materials and may be autologous, meaning each batch is linked to an individual patient. 

From a quality perspective, this distinction fundamentally alters how risk, control, and assurance must be applied across the product lifecycle. 

Unique Quality Management Challenges in ATMP Development 

ATMP manufacturing introduces challenges that extend beyond conventional GMP frameworks. Patient-derived starting materials, specialised cleanroom environments, and strict environmental controls require tailored Quality Management System (QMS) approaches from early development through commercial supply. 

Biological variability in donor material, aseptic processing risks, equipment performance during cell expansion, and vulnerabilities in temperature-controlled logistics all introduce additional quality risks. These factors demand enhanced monitoring, robust risk management strategies, and close integration between Quality Assurance, manufacturing, and clinical teams. 

Small batch sizes and short shelf lives further intensify quality oversight requirements. When a single batch serves a single patient, traditional end-product testing alone is insufficient. Instead, enhanced traceability, chain of identity controls, and adapted quality control strategies become essential to safeguarding patient safety. 

Starting Materials: Managing High-Risk Biological Inputs 

One of the most significant differences between ATMPs and traditional pharmaceuticals lies in their starting materials. 

Conventional pharmaceutical manufacturing relies on well-characterised chemical active pharmaceutical ingredients (APIs) produced under tightly controlled conditions. These materials demonstrate high consistency and stability across batches. 

ATMPs, by contrast, rely on human cells and tissues as starting materials. Donor variability, eligibility assessment, screening requirements, and ethical considerations introduce inherent risks that cannot be eliminated through standardisation alone. 

Quality oversight for ATMPs therefore extends beyond traditional GMP controls to include donor qualification, informed consent governance, and robust chain of identity and chain of custody systems. Maintaining control over these elements is critical to ensuring product safety, integrity, and clinical outcome. 

Manufacturing Is the Product 

For traditional pharmaceuticals, a validated manufacturing process ensures consistent product quality provided operations remain within defined parameters. 

For ATMPs, the relationship between process and product is fundamentally different. Even minor process changes can affect potency, cellular phenotype, viability, or safety profile. As a result, quality oversight must be deeply embedded into process development and ongoing manufacturing operations. 

Change management becomes significantly more complex, requiring strong scientific justification, comprehensive risk assessment, and robust comparability strategies. Process validation is no longer a one-time activity but a lifecycle-based exercise supported by continuous monitoring and increasing process knowledge. 

Scale, Batch Size, and Release: Rethinking Quality Control 

Traditional pharmaceutical manufacturing benefits from large batch sizes, extensive sampling, and statistically supported release testing models. 

ATMP manufacturing operates under a different reality. Batch sizes are often extremely small, sometimes limited to a single patient dose. Material availability for testing is constrained, and shelf lives are short, placing significant pressure on release timelines. 

As a result, quality oversight must shift toward process-based assurance. Greater reliance is placed on in-process controls, rapid or alternative microbiological testing methods, and scientifically justified conditional or parametric release strategies. In ATMPs, quality is increasingly built into the process rather than confirmed solely at final release. 

Supply Chain Complexity as a Quality Risk 

Traditional pharmaceutical supply chains typically follow a linear and relatively stable pathway from manufacturer to patient. 

ATMP supply chains are far more complex and time-sensitive. They may involve donor or patient material collection, transport to specialised manufacturing sites, cryogenic shipment, delivery to clinical centres, and administration at the bedside. 

Maintaining strict temperature control, full traceability, and an unbroken chain of identity is therefore critical. In ATMPs, supply chain management becomes an integral part of quality oversight rather than a purely logistical function. 

Risk-Based GMP and Regulatory Expectations 

EudraLex Volume 4, Part IV recognises that ATMPs require a risk-based application of GMP principles due to their scientific complexity and manufacturing constraints. 

Regulators expect organisations to justify adaptations to traditional approaches through sound scientific rationale. This includes explaining validation limitations, applying appropriate testing strategies, and maintaining a robust Pharmaceutical Quality System supported by deep process understanding and close collaboration between Quality Assurance and manufacturing teams.

This is not reduced GMP. It is adaptive GMP, where compliance is achieved through science and risk-based application of established principles. 

Where Traditional Pharmaceutical Quality Still Applies 

Despite the unique challenges of ATMPs, many foundational pharmaceutical quality principles remain essential, including: 

• Robust Quality Management Systems 

• Data integrity and documentation control 

• Deviation management and CAPA effectiveness 

• Supplier qualification and oversight 

• Qualified Person (QP) certification prior to release 

However, in ATMPs, quality can no longer function solely as an end-stage oversight activity. It must be embedded, scientific, and agile to support evolving manufacturing models and patient-specific therapies. 

Common Inspection Findings in ATMP Quality Systems 

Regulatory inspections and assessments frequently highlight recurring weaknesses in ATMP quality systems, including: 

• Inadequate donor traceability controls 

• Weak chain of identity management 

• Insufficient comparability data following process changes 

• Inadequate environmental control for open manipulations 

• Overreliance on development-stage controls in commercial supply 

These findings reinforce the need to establish mature quality systems early. In ATMPs, quality, compliance, and control cannot be deferred until late-stage development. 

Four Focus Areas for an Effective ATMP Quality Strategy 

Product and Process Knowledge 
Develop a deep understanding of product characteristics, critical process parameters, equipment performance, and facility controls to ensure consistent quality and clinical performance. 

Supplier and Outsourced Activity Oversight 
Maintain robust qualification and oversight of suppliers, CMOs, and CROs through audits, Quality Technical Agreements, and ongoing performance monitoring. 

Documentation and Data Governance 
Implement structured documentation frameworks that ensure data integrity, traceability, and informed decision-making across the entire product lifecycle.

Competency and Knowledge Management 
Invest in training, clearly defined roles, and internal expertise to ensure quality systems remain effective as operations evolve. 

Quality as a Strategic Enabler in Advanced Therapies 

Transitioning from traditional pharmaceuticals to ATMPs requires a fundamental mindset shift: 

• From compliance-driven QA to science-integrated QA 

• From large-scale repeatability to variability management 

• From stable product lifecycles to rapid innovation cycles 

In ATMPs, quality is not just a gatekeeper. It is a strategic enabler of patient safety, regulatory success, and sustainable commercialisation.